Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

被引:30
|
作者
Hikichi, Taiichi [1 ]
Agarie, Mitsuko [2 ]
机构
[1] Hikichi Eye Clin, Sapporo, Hokkaido, Japan
[2] Carl Zeiss Meditec Co Ltd, Tokyo, Japan
关键词
anti-VEGF; choriocapillaris; neovascular age-related macular degeneration; optical coherence tomography angiography; vessel density; COHERENCE TOMOGRAPHY ANGIOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY; RETINAL-PIGMENT EPITHELIUM; FOVEAL AVASCULAR ZONE; ANTI-VEGF TREATMENT; QUANTITATIVE-ANALYSIS; VASCULAR DENSITY; RANIBIZUMAB; ATROPHY;
D O I
10.1167/iovs.18-24522
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). METHODS. Japanese patients with nAMD with a history of long-term anti-VEGF monotherapy at study entry were studied retrospectively. OCTA images were obtained, and the vessel densities (mm(-1)) of the superficial capillary plexus, deep capillary plexus (DCP), choriocapillaris (CC), and the plexus foveal avascular zone area (mm(2)) were calculated. RESULTS. One hundred twenty-four eyes (124 patients) were included. The mean +/- standard deviation follow-up period between the first and last OCTA imaging sessions was 14.5 +/- 3.1 months; the duration of the anti-VEGF monotherapy before the first OCTA imaging session was 68.0 +/- 23.6 months, with a mean of 3.6 +/- 3.0 injections during the follow-up period. The vessel densities of the DCP and CC significantly decreased (P = 0.001 and P = 0.009, respectively) from 10.62 +/- 2.72 mm(-1) and 11.84 +/- 1.79 mm(-1) to 9.44 +/- 2.88 mm(-1) and 11.18 +/- 2.12 mm(-1). Such findings were not observed in 63 control eyes. CONCLUSIONS. The DCP and CC deteriorate during treatment. This information may guide future treatment strategies for nAMD, such as the need to protect the capillaries to maintain visual acuity after long-term treatment. Prospective, controlled trials are required to confirm our findings.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 50 条
  • [41] Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
    Cheema, Muhammad Raza
    DaCosta, Joanna
    Talks, James
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 279 - 287
  • [42] Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration
    Boyle, Jessica
    Vukicevic, Meri
    Koklanis, Konstandina
    Itsiopoulos, Catherine
    Rees, Gwyneth
    PSYCHOLOGY HEALTH & MEDICINE, 2018, 23 (02) : 127 - 140
  • [43] Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials
    Nguyen, Chu Luan
    Oh, Lawrence J.
    Wong, Eugene
    Wei, Joe
    Chilov, Michael
    BMC OPHTHALMOLOGY, 2018, 18
  • [44] Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration
    Abdolrahimzadeh, Solmaz
    Gharbiya, Magda
    Formisano, Martina
    Bertini, Fabrizio
    Cerini, Alberto
    Pacella, Elena
    CURRENT EYE RESEARCH, 2019, 44 (09) : 1000 - 1005
  • [45] INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POOR VISUAL ACUITY
    Song, Jae Shin
    Kim, Min Seok
    Joo, Kwangsic
    Park, Sang Jun
    Woo, Se Joon
    Park, Kyu Hyung
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2024, 44 (09): : 1486 - 1494
  • [46] Status of Usage of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration
    Cho, Songhee
    Shin, Sang Jin
    Suh, Jae Kyung
    Tchoe, Hajin
    Kang, Min Joo
    Yang, Jangmi
    Jee, Donghyun
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2019, 60 (08): : 758 - 764
  • [47] Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
    Baris, Mine Esen
    Mentes, Jale
    Afrashi, Filiz
    Nalcaci, Serhad
    Akkin, Cezmi
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2020, 50 (05): : 275 - 282
  • [48] Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents
    Moreira Kanadani, Tereza Cristina
    Veloso, Carlos Eduardo
    Nehemy, Marcio B.
    OPHTHALMOLOGICA, 2018, 240 (04) : 200 - 207
  • [49] Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset
    Mones, Jordi
    Singh, Rishi P.
    Bandello, Francesco
    Souied, Eric
    Liu, Xin
    Gale, Richard
    OPHTHALMOLOGICA, 2020, 243 (01) : 1 - 8
  • [50] Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration
    Ciulla, Thomas A.
    Rosenfeld, Philip J.
    CURRENT OPINION IN OPHTHALMOLOGY, 2009, 20 (03) : 158 - 165